Gilead Science, an American biopharmaceutical company, completed the acquisition of Kite Pharma, a developer of cancer immunotherapy products, for $11.9bn. “We are excited to welcome more than 700 talented Kite employees to the Gilead organization. Throughout our respective histories, each company has demonstrated a deep commitment to advancing life-saving therapies for people who need them. I look forward to all that we will accomplish together, as a combined organization,” John F. Milligan, Gilead President and Chief Executive Officer.